Brief: Cardiol Therapeutics Cash And Cash Equivalents Of $34.9 mln As Of Dec 31, 2023, Which Funds Operations Into 2026
02/04/2024 11:13
April 2 (Reuters) - Cardiol Therapeutics Inc CRDL.TO :
* CARDIOL THERAPEUTICS: CASH AND CASH EQUIVALENTS OF $34.9
MILLION AS OF DEC 31, 2023, WHICH FUNDS OPERATIONS INTO 2026
Source text for Eikon: ID:n0001062993-24-007668
Further company coverage: CRDL.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cardiol Therapeutics
See all newsBrief: Cardiol Therapeutics Achieves Phase III Maveric Enrollment Target Ahead Of Schedule And Expands Pivotal Trial To Strengthen Assessment Of Cardiolrx's Efficacy
Brief: Cardiol Therapeutics Files US$150 Million Preliminary Base Shelf Prospectus
Brief: Cardiol Therapeutics Files For Mixed Shelf Offering Of Up To $150 Mln
Brief: Cardiol Therapeutics Initiated Pivotal Phase Iii Maveric Trial Of Cardiolrx In Recurrent Pericarditis
NASDAQ RESUMED AT 09:00 AM